Chimera Bioengineering

Chimera Bioengineering is pioneering a novel approach to cell therapy by developing CAR-T cells with precisely controlled genetic programming. Their core technology, the GOLD PLATFORM™, includes components like MERCURY™ for tuning CAR expression and GOLD CONTROL™ for regulating therapeutic payloads, addressing key challenges of insufficient activity and excessive toxicity in current cell therapies. The company is independently advancing several solid tumor and blood cancer programs toward clinical trials while seeking strategic collaborations to validate and expand its platform. Their mission is to transform the promise of cell therapies into effective, safe treatments that restore dignity to cancer patients.

The GOLD PLATFORM™ is a suite of native T-cell inspired genetic engineering technologies that precisely control gene expression in cell therapies, including GOLD CONTROL™ for payload regulation and MERCURY™ for tunable CAR expression.

Total raised: $29M

Chimera faces competition from large pharma with approved CAR-T products and numerous biotechs developing next-generation approaches. Differentiation centers on using native T-cell control mechanisms rather than synthetic biology, aiming for more physiological regulation and potentially better safety profiles.